Acceleron Pharma (NASDAQ:XLRN) will post its quarterly earnings results after the market closes on Thursday, February 25th. Analysts expect Acceleron Pharma to post earnings of ($0.67) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
XLRN opened at $141.39 on Tuesday. The company has a market capitalization of $8.52 billion, a P/E ratio of -54.59 and a beta of 0.59. The firm’s fifty day moving average price is $124.63 and its two-hundred day moving average price is $114.10. Acceleron Pharma has a fifty-two week low of $66.44 and a fifty-two week high of $143.62.
In other Acceleron Pharma news, SVP Adam M. Veness sold 2,056 shares of the firm’s stock in a transaction that occurred on Tuesday, January 5th. The shares were sold at an average price of $122.56, for a total value of $251,983.36. Following the transaction, the senior vice president now directly owns 18,219 shares of the company’s stock, valued at $2,232,920.64. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Habib J. Dable sold 4,258 shares of the firm’s stock in a transaction that occurred on Tuesday, January 5th. The shares were sold at an average price of $121.13, for a total transaction of $515,771.54. Following the completion of the transaction, the chief executive officer now directly owns 86,046 shares in the company, valued at $10,422,751.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,622 shares of company stock worth $8,025,691. Insiders own 2.50% of the company’s stock.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease.
Read More: What are catch-up contributions?
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.